Larisa V. Mekheda
Larisa V. Mekheda has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Liliya Y. Fomina
ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Министерства здравоохранения Российской Федерации
3 shared publications - Alexander Mikhailovich Scherbakov
N.N. Blokhin National Medical Research Center of Oncology, Kashirskoye shosse 24, Moscow 115522, Russia
2 shared publications - Alice S. Vilkova
N.N. Blokhin NMRCO, 115478 Moscow, Russia
2 shared publications - Angelika E. Manikaylo
N.N. Blokhin NMRCO, 115478 Moscow, Russia
2 shared publications - Beniamin Yu. Bokhyan
Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia
2 shared publications - Denis A. Burov
N.N. Blokhin NMRCO, 115478 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 7 March 2023
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (1) , 30-37
Molecular and genetic aspects of pathogenesis: somatic and germline mutations
Меланома имеет самую высокую мутационную нагрузку среди солидных опухолей. Идентифицировано множество связанных с меланомой соматических и герминальных мутаций в генах, ряд из которых так называемых «драйверных генов», вероятнее всего, включаются в опухолевую прогрессию и являются основными в молекулярной классификации меланомы. В этой части обзора приведен анализ изменений в генах KIT, NF1 RAC1, в зависимости от источника первичной опухоли. Приводятся последние данные о герминальных и соматических мутациях в генах CDKN2A, BAP1, TERT, MITF и др., обнаруженных в меланоме, анализ которых позволяет дополнить знания о причинных механизмах возникновения заболевания.
- 7 March 2023
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (1) , 30-37
Open AccessMolecular and genetic aspects of pathogenesis: somatic and germline mutations
Меланома имеет самую высокую мутационную нагрузку среди солидных опухолей. Идентифицировано множество связанных с меланомой соматических и герминальных мутаций в генах, ряд из которых так называемых «драйверных генов», вероятнее всего, включаются в опухолевую прогрессию и являются основными в молекулярной классификации меланомы. В этой части обзора приведен анализ изменений в генах KIT, NF1 RAC1, в зависимости от источника первичной опухоли. Приводятся последние данные о герминальных и соматических мутациях в генах CDKN2A, BAP1, TERT, MITF и др., обнаруженных в меланоме, анализ которых позволяет дополнить знания о причинных механизмах возникновения заболевания.
- Open Access
- 27 December 2022
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 68 (6) , 725-732
Melanoma, molecular and genetic aspects of etiopathogenesis: classification, epidemiology, risk factors, braf and nras mutations
Melanoma belongs to malignant tumors that are at a high risk of early metastatic spreading and have a high mortality rate. Data from the majority of countries demonstrate a rapid increase of the incidence of melanoma. The most important environmental risk factors are the exposure to ultraviolet rays and quantity of melanocytic nevi. Genome wide association studies of melanoma has allowed to identify the complex mutational profile which has shown intratumoral microheterogeneity of melanoma that leads to difficulty of its treatment. The current review provides information on epidemiological, clinical characteristics of (malignant) melanoma^ and analysis of risk factors and genetic changes in the BRAF and NRAS genes for different forms of melanoma has been performed, depending on the localisation of the primary tumor (skin, mucosal, uveal). A variety of oncogenic changes in nevi and subtypes of melanoma associated and non-associated with solar exposure are discussed. Меланома относится к злокачественным опухолям со склонностью к раннему метастазированию и высокой смертностью, несмотря на современные возможности лечения. Развитие молекулярно-генетических технологий позволило выявить сложный мутационный состав, показавший внутриопухолевую микрогетерогенность меланомы, приводящий к трудности её лечения. Идентифицировано множество связанных с меланомой соматических и герминальных мутаций в генах, ряд которых, так называемые «драйверные гены», вероятнее всего включаются в опухолевую прогрессию и являются основными в молекулярной классификации меланомы. В обзоре представлены эпидемиологические, клинические и патологические характеристики меланомы, проведен анализ факторов риска и генетических изменений в генах BRAF, NRAS, KIT, NF1, RAC1 для разных форм меланомы в зависимости от источника первичной опухоли (кожа, слизистые оболочки, оболочки глаза). Обсуждаются разнообразные онкогенные изменения в невусах и подтипах меланомы, связанных и не связанных с солнечной экспозицией. Приводятся данные о герминальных и соматических мутациях в генах CDKN2A, BAP1, TERT, MITF и др., обнаруженных в меланоме, анализ которых позволяет дополнить знания о причинных механизмах возникновения заболевания.
- 27 December 2022
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 68 (6) , 725-732
Open AccessMelanoma, molecular and genetic aspects of etiopathogenesis: classification, epidemiology, risk factors, braf and nras mutations
Melanoma belongs to malignant tumors that are at a high risk of early metastatic spreading and have a high mortality rate. Data from the majority of countries demonstrate a rapid increase of the incidence of melanoma. The most important environmental risk factors are the exposure to ultraviolet rays and quantity of melanocytic nevi. Genome wide association studies of melanoma has allowed to identify the complex mutational profile which has shown intratumoral microheterogeneity of melanoma that leads to difficulty of its treatment. The current review provides information on epidemiological, clinical characteristics of (malignant) melanoma^ and analysis of risk factors and genetic changes in the BRAF and NRAS genes for different forms of melanoma has been performed, depending on the localisation of the primary tumor (skin, mucosal, uveal). A variety of oncogenic changes in nevi and subtypes of melanoma associated and non-associated with solar exposure are discussed. Меланома относится к злокачественным опухолям со склонностью к раннему метастазированию и высокой смертностью, несмотря на современные возможности лечения. Развитие молекулярно-генетических технологий позволило выявить сложный мутационный состав, показавший внутриопухолевую микрогетерогенность меланомы, приводящий к трудности её лечения. Идентифицировано множество связанных с меланомой соматических и герминальных мутаций в генах, ряд которых, так называемые «драйверные гены», вероятнее всего включаются в опухолевую прогрессию и являются основными в молекулярной классификации меланомы. В обзоре представлены эпидемиологические, клинические и патологические характеристики меланомы, проведен анализ факторов риска и генетических изменений в генах BRAF, NRAS, KIT, NF1, RAC1 для разных форм меланомы в зависимости от источника первичной опухоли (кожа, слизистые оболочки, оболочки глаза). Обсуждаются разнообразные онкогенные изменения в невусах и подтипах меланомы, связанных и не связанных с солнечной экспозицией. Приводятся данные о герминальных и соматических мутациях в генах CDKN2A, BAP1, TERT, MITF и др., обнаруженных в меланоме, анализ которых позволяет дополнить знания о причинных механизмах возникновения заболевания.
- Open Access
Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
Soft tissue sarcomas (STS) are heterogeneous cancers with more than 100 histological subtypes, different in molecular alterations, which make its personalized therapy very complex. Gold standard of chemotherapy for advanced STS includes combinations of Doxorubicin and Ifosfamide or Gemcitabine and Docetaxel. Chemotherapy is efficient for less than 50% of patients and it is followed by a fast development of drug resistance. Our study was directed to the search of genetic alterations in cancer cells associated with chemoresistance of undifferentiated pleomorphic and synovial sarcomas to the abovementioned genotoxic drugs. We analyzed chemoresistance of cancer cells in vitro using primary STS cultures and performed genetic analysis for the components of apoptotic signaling. In 27% of tumors, we revealed alterations in TP53, ATM, PIK3CB, PIK3R1, NTRK1, and CSF2RB. Cells from STS specimens with found genetic alterations were resistant to Dox, excluding the only one case when TP53 mutation resulted in the substitution Leu344Arg associated with partial oligomerization loss and did not cause total loss of TP53 function. Significant association between alterations in the components of apoptosis signaling and chemoresistance to Dox was found. Our data are important to elaborate further the therapeutic strategy for STS patients with alterations in apoptotic signaling.
Open AccessSoft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
Soft tissue sarcomas (STS) are heterogeneous cancers with more than 100 histological subtypes, different in molecular alterations, which make its personalized therapy very complex. Gold standard of chemotherapy for advanced STS includes combinations of Doxorubicin and Ifosfamide or Gemcitabine and Docetaxel. Chemotherapy is efficient for less than 50% of patients and it is followed by a fast development of drug resistance. Our study was directed to the search of genetic alterations in cancer cells associated with chemoresistance of undifferentiated pleomorphic and synovial sarcomas to the abovementioned genotoxic drugs. We analyzed chemoresistance of cancer cells in vitro using primary STS cultures and performed genetic analysis for the components of apoptotic signaling. In 27% of tumors, we revealed alterations in TP53, ATM, PIK3CB, PIK3R1, NTRK1, and CSF2RB. Cells from STS specimens with found genetic alterations were resistant to Dox, excluding the only one case when TP53 mutation resulted in the substitution Leu344Arg associated with partial oligomerization loss and did not cause total loss of TP53 function. Significant association between alterations in the components of apoptosis signaling and chemoresistance to Dox was found. Our data are important to elaborate further the therapeutic strategy for STS patients with alterations in apoptotic signaling.
- Open Access
- 16 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3183
Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells
Chemotherapy of soft tissue sarcomas (STS) is restricted by low chemosensitivity and multiple drug resistance (MDR). The purpose of our study was the analysis of MDR mechanism in different types of STS. We assessed the expression of ABC-transporters, MVP, YB-1, and analyzed their correlation with chemosensitivity of cancer cells. STS specimens were obtained from 70 patients without metastatic disease (2018–2020). Expression level of MDR-associated genes was estimated by qRT-PCR and cytofluorimetry. Mutations in ABC-transporter genes were captured by exome sequencing. Chemosensitivity (SI) of STS to doxorubicin (Dox), ifosfamide (Ifo), gemcitabine (Gem), and docetaxel (Doc) was analyzed in vitro. We found strong correlation in ABCB1, ABCC1, and ABCG2 expression. We demonstrated strong negative correlations in ABCB1 and ABCG2 expression with SI (Doc) and SI (Doc + Gem), and positive correlation of MVP expression with SI (Doc) and SI (Doc + Gem) in undifferentiated pleomorphic sarcoma. Pgp expression was shown in 5 out of 44 STS samples with prevalence of synovial sarcoma relapses and it is strongly correlated with SI (Gem). Mutations in MDR-associated genes were rarely found. Overall, STS demonstrated high heterogeneity in chemosensitivity that makes reasonable in vitro chemosensitivity testing to improve personalized STS therapy, and classic ABC-transporters are not obviously involved in MDR appearance.
- 16 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3183
Open AccessAnalysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells
Chemotherapy of soft tissue sarcomas (STS) is restricted by low chemosensitivity and multiple drug resistance (MDR). The purpose of our study was the analysis of MDR mechanism in different types of STS. We assessed the expression of ABC-transporters, MVP, YB-1, and analyzed their correlation with chemosensitivity of cancer cells. STS specimens were obtained from 70 patients without metastatic disease (2018–2020). Expression level of MDR-associated genes was estimated by qRT-PCR and cytofluorimetry. Mutations in ABC-transporter genes were captured by exome sequencing. Chemosensitivity (SI) of STS to doxorubicin (Dox), ifosfamide (Ifo), gemcitabine (Gem), and docetaxel (Doc) was analyzed in vitro. We found strong correlation in ABCB1, ABCC1, and ABCG2 expression. We demonstrated strong negative correlations in ABCB1 and ABCG2 expression with SI (Doc) and SI (Doc + Gem), and positive correlation of MVP expression with SI (Doc) and SI (Doc + Gem) in undifferentiated pleomorphic sarcoma. Pgp expression was shown in 5 out of 44 STS samples with prevalence of synovial sarcoma relapses and it is strongly correlated with SI (Gem). Mutations in MDR-associated genes were rarely found. Overall, STS demonstrated high heterogeneity in chemosensitivity that makes reasonable in vitro chemosensitivity testing to improve personalized STS therapy, and classic ABC-transporters are not obviously involved in MDR appearance.